ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC
´ëÇѺ´¸®ÇÐȸÁö 2011³â 45±Ç 1È£ p.45 ~ p.52
·ùÇѼ®(Ryu Han-Suk) - Seoul National University College of Medicine Department of Pathology
(Xu Xianhua) - Seoul National University College of Medicine Department of Pathology
±èÈ¿Áø(Kim Hyo-Jin) - Seoul National University College of Medicine Department of Pathology
ÀÌÁ¾¼÷(Lee Jong-Suk) - Seoul National University College of Medicine Department of Thoracic Surgery
Àü»óÈÆ(Jheon Sang-Hoon) - Seoul National University College of Medicine Department of Internal Medicine
Á¤ÁøÇà(Chung Jin-Haeng) - Seoul National University Bundang Hospital Department of Pathology
Abstract
Background : The role of excision repair cross-complementation group 1 (ERCC1) has been controversial in non-small cell lung cancer (NSCLC) patients who received adjuvant chemotherapy with a platinum agent. We investigated ERCC1 expression in stage I-II NSCLC to clarify its signifi-cance for adjuvant chemotherapy.
Methods : The ERCC1 expression profile was evaluated by immunohistochemistry and compared according to adjuvant chemotherapeutic agents in 146 patients who underwent surgical resection for stage I-II NSCLC. The patients were divided into 3 groups; adjuvant chemotherapy with a platinum based agent (18.5%, 27/146); adjuvant chemotherapy with uracil-tegafur (UFT) (40.4%, 59/146); surgery-alone (41.1%, 60/146).
Results : Nuclear ERCC1 expression was detected in 71.9% (105/146) of NSCLC and was significantly associated with a shortened survival period in the group 1 patients who received the platinum based regimen after surgery. The group 2 patients who received UFT showed the longest survival period, followed by the surgery-alone group (overall survival, p=0.049; disease-free survival [DFS], p<0.001).
Conclusions : These results suggest that stage I-II NSCLC patients with ERCC1 expression experience a shorter DFS period with adjuvant chemotherapy with a platinum based regimen and may benefit from adjuvant chemotherapy with UFT, instead of platinum after surgery.
Å°¿öµå
Carcinoma, non-small-cell lung, ERCC1 protein, human, Chemotherapy, adjuvant
KMID :
0357920110450010045
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
stage I-II NSCLC patients with ERCC1 expression experience a shorter DFS period with adjuvant chemotherapy with a platinum based regimen and may benefit from adjuvant chemotherapy with UFT, instead of platinum after surgery.